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ABSTRACT
Introduction: For the past few decades, condoms
have been the main method of HIV prevention. Recent
advances in antiretroviral (ARV)-based prevention
products have substantially changed the prevention
landscape, yet little is known about how popular these
products will be among potential users, or whether
new methods might be used in conjunction with, or
instead of, condoms. This study will use a discrete
choice experiment (DCE) to (1) explore potential users’
preferences regarding HIV prevention products, (2)
quantify the importance of product attributes and (3)
predict the uptake of products to inform estimates of
their potential impact on the HIV epidemic in South
Africa. We consider preferences for oral pre-exposure
prophylaxis; a vaginal microbicide gel; a long-acting
vaginal ring; a SILCS diaphragm used in concert with
gel; and a long-acting ARV-based injectable.
Methods and analysis: This study will gather data
from 4 populations: 200 women, 200 men, 200
adolescent girls (aged 16–17 years) and 200 female
sex workers. The DCE attributes and design will be
developed through a literature review, supplemented
by a thematic analysis of qualitative focus group
discussions. Extensive piloting will be carried out in
each population through semistructured interviews.
The final survey will be conducted using computer
tablets via a household sample (for women, men and
adolescents) and respondent-driven sampling (for
female sex workers), and DCE data analysed using a
range of multinomial logit models.
Ethics and dissemination: This study has been
approved by the University of the Witwatersrand
Human Research Ethics Committee and the Research
Ethics Committee at the London School of Hygiene
and Tropical Medicine. Findings will be presented to
international conferences and peer-reviewed journals.
Meetings will be held with opinion leaders in South
Africa, while results will be disseminated to
participants in Ekurhuleni through a public meeting
or newsletter.
INTRODUCTION
Despite intense efforts to reduce HIV inci-
dence, its estimated prevalence remains high
in South Africa. The fourth national
population-based survey conducted by the
Human Sciences Research Council, esti-
mated prevalence to be 12.6% in 2012, an
increase on the previous survey estimate of
10.9% in 2008.1 This increase may be
explained partly by expanded access to anti-
retroviral (ARV) treatments and associated
reductions in mortality, however, there is also
evidence of continued sexual transmission of
HIV in those aged 15 years or older. HIV
Strengths and limitations of this study
▪ This study uses a novel discrete choice experi-
ment (DCE) to elicit people’s preferences for
new antiretroviral (ARV)-based HIV prevention
products.
▪ The results of the DCE will allow us to explore
how respondents value different product
characteristics. We will also be able to predict
whether products will be used alongside, or
instead of condoms, a critical element of asses-
sing their potential impact.
▪ We will draw out policy recommendations from
our findings, in particular informing mathemat-
ical models to evaluate the impact and cost-
effectiveness of a range of new prevention
products.
▪ The DCE choice tasks are hypothetical in nature
and will be carried out in Ekurhuleni
Metropolitan Municipality, near Johannesburg,
South Africa. The results may not be generalis-
able to other settings. Female sex workers will
be recruited through respondent-driven sam-
pling, rather than a randomised method.
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infection is not borne equally in the South African
population; women are 1.4 times more likely to be living
with HIV compared to men, while adolescent girls (aged
15–19 years) are at 8 times greater risk of being HIV
positive than boys of the same age.1 Female sex workers
(FSWs) are designated a key population for HIV treat-
ment and prevention activities, and are around four
times more likely to be living with HIV than South
African women of reproductive age from the general
population.2 3
The HIV prevention landscape continues to shift sub-
stantially, not least due to emerging evidence that ARV
drugs can be used for HIV prevention. The HPTN 052
trial demonstrated the ability of ARVs to reduce the
infectiousness of HIV positive persons through suppres-
sing viral loads, and led to the development of
treatment-as-prevention programming.4 Furthermore,
ARV-based oral pre-exposure prophylaxis (PrEP) has
been shown to offer a high degree of protection from
HIV acquisition in different populations and contexts
worldwide.5–9 In 2012, WHO recommended oral PrEP
for use in speciﬁc ‘high-risk’ populations, such as sero-
discordant couples. This recommendation was broa-
dened in September 2015 with PrEP recommended for
any person at ‘substantial risk’ of HIV acquisition, and
not necessarily restricted to those in key populations.10
Despite the success and subsequent licensure of oral
PrEP, there is an increasing recognition that the
characteristics of effective prevention options may vary
across different population groups. It is important that
prevention options are tailored to ﬁt well with the life-
styles of potential users, and recent efforts have focused
on developing novel methods of delivering ARV drugs
for HIV prevention. Outside of oral PrEP, there are
numerous products in various stages of development
including: vaginal microbicide gels used daily or at every
sex act; long-acting vaginal rings; a SILCS diaphragm
used in concert with gel; and long-acting injectable
products.5 6 8 11–13
Problems with adherence have plagued clinical trials
of shorter-acting products such as microbicide gels, high-
lighting the need for methods that are attractive and
easy for people to use.6 9 The development of longer
acting products, such as the monthly applied vaginal
ring or the three-monthly injection, has the potential to
increase adherence, uptake and thus effective cover-
age.14 15 However, until products have been developed
and rolled out to a population, it is difﬁcult to accurately
predict whether or how much they will be used, or
whether they will be used in addition to, or instead of
condoms which offer multipurpose protection.16
Attention has also turned to the potential for new pro-
ducts to meet the broader reproductive and sexual
health needs of many individuals. These needs are not
limited to protection against HIV and other sexually
transmitted infections (STIs), but also access to safe and
reliable contraceptives. Currently, the only products
which protect against HIV, STIs and unwanted
pregnancies are the male and female condoms, and so
there may be demand for additional product choices
which confer combination protection. As such, consider-
able research has focused on developing multipurpose
technologies (MPTs) which offer protection against HIV,
STIs and pregnancy.17 Efﬁcacy trials for MPTs are
planned and products could be made available on the
market in the next decade.11 14
In the context of these advances in the ﬁeld of HIV
prevention, it is important to identify and explore the
determinants of demand for new technologies.
Understanding user preferences can not only assist pre-
vention efforts by predicting product uptake, but also
help reﬁne the development of new products. We plan
to undertake a study that will use a discrete choice
experiment (DCE) to quantify potential users’ stated
preferences of ARV-based prevention products in a
South African setting, predict uptake of new products,
and assess the extent to which condom use might be
reduced following their introduction.
DCEs are, theoretically, robust economic tools, and
can be particularly informative when there are little or
no data on observed behaviour.18–20 DCEs ask people to
choose between a number of hypothetical scenarios,
where each choice is described by a set of attributes. By
assessing how choices vary according to different attri-
bute levels, researchers are able to assess what is import-
ant to people as they choose. Furthermore, DCEs allow
researchers to quantitatively elicit the key drivers of indi-
viduals’ decisions, and can predict future behaviour.21
DCE methods have been used extensively in ﬁelds of
applied economics, particularly transport and environ-
mental economics.22–24 In health, they have been
applied across a range of disease prevention areas
including voluntary medical male circumcision, vaccin-
ation, STI treatment and contraception.25–28
A particularly novel use of this research will be for sub-
sequent work to integrate DCE-derived uptake predic-
tions from this study within an infectious disease-
modelling framework to estimate the potential impact
and cost-effectiveness of introducing new HIV preven-
tion products. Such models often rely on assumed levels
of uptake based on expert opinion, or uptake of similar
interventions.29 These assumptions are frequently not
based on data, and so are likely to produce inaccurate
projections. This study will build on previous research
suggesting that DCEs may provide more data-driven,
dynamic and realistic estimates of product uptake in the
absence of observed data.30
METHODS AND ANALYSIS
Overview of approach and methods
This study will build on previous mixed-methods research
to explore consumer preferences for HIV prevention pro-
ducts in South Africa. Primary formative research will be
carried out among target groups before the implementa-
tion of a survey with 800 participants: 200 men and 200
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women aged between 18 and 45 years, randomly sampled
from the general population, 200 adolescent girls (aged
between 16 and 17 years), also randomly sampled from
the general population, and 200 FSWs sampled using
respondent-driven sampling, a common approach for col-
lecting data from hard-to-reach populations.31
The DCE will be carried out among all self-reported
HIV-negative persons sampled. Although self-reported
HIV status is not necessarily a reliable indicator of seros-
tatus, it can still be useful for hypothetical DCE surveys,
assuming that respondents answer according to their
perceived HIV status. In an effort to maximise reporting
accuracy, we will use an experienced team of inter-
viewers with additional training, focusing on making par-
ticipants comfortable, and reinforcing conﬁdentiality
throughout the interview.
A 2005 study in the same municipality used qualitative
focus group discussions (FGDs) and individual inter-
views to develop a DCE on a set of HIV prevention pro-
ducts under development at the time.29 The research
identiﬁed which product characteristics (or attributes)
consumers valued, how the levels of these might vary,
and optimal ways to present these to participants in a
choice experiment. To develop relevant and meaningful
choice tasks, the current study will build on this previous
formative research, alongside an updated review of the
literature, and intensive piloting with each population.
In a DCE, respondents are presented with a number
of options which are each described by attributes of par-
ticular levels. Respondents are ﬁrst asked to choose their
most favoured option from two or more alternatives, and
then they continue with this process which is repeated
over a number of different choice sets. Attribute levels
are systematically varied between sets according to an
experimental design which aims to maximise the statis-
tical efﬁciency of data collection. For each choice set, it
is assumed that respondents choose the scenario which
would give them the most beneﬁt, and choices are,
therefore, indicative of an underlying utility function.
Econometric analysis of DCE data estimates the utility
functions of respondents which quantitatively weights
the value placed on each attribute. A more detailed ana-
lysis is possible through the inclusion of sociodemo-
graphic or other information as explanatory variables in
these functions.32
DCEs give a quantitative indication of the strength of
an individual’s preference for one attribute (such as efﬁ-
cacy in preventing HIV infection) relative to another
(such as frequency of application). Results from DCEs
are conducive to directly informing policy by allowing
inference of the key drivers of individual behaviour in
responding to different policy environments, and enable
the simulation of how choices might change under dif-
ferent circumstances. An example of a DCE is shown in
ﬁgure 1, where ﬁgure 1A represents a vaginal ring, and
ﬁgure 1B and 1C different injectable products. The
opt-out alternative in the ﬁnal column will be presented
as what a respondent reported using in their last sexual
encounter, that is, the attributes of a condom if the par-
ticipant used a condom, or the characteristics of using
no protection otherwise. This is to allow the estimation
of unconditional demand for new products.
The study design is shown in ﬁgure 2, and consists of
three stages: an extensive formative phase (including
generating an initial design, piloting and pretesting of
the DCE), implementation of the DCE and data analysis
and publication. The DCE design began in July 2015
and piloting in September 2015. Data collection for the
ﬁnal DCE is expected to be carried out between
October and December 2015. This study will conform to
the best-practice guidelines of the International Society
for Pharmacoeconomics and Outcomes Research
Figure 1 Example of a discrete choice experiment choice task to elicit HIV prevention product preferences from HIV negative
women.
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Guidelines for Good Research Practices for conjoint
analysis in health.33
Stage 1: formative phase—development and piloting
of choice tasks, attributes and levels
A thematic analysis of qualitative data gathered in an
earlier study29 led to the identiﬁcation of key attributes
which were important to the respondents’ choice of a
HIV prevention product. These will be explored in the
context of more recent literature to account for evolu-
tion in the HIV prevention ﬁeld, for example, changes
in technology (eg, product efﬁcacy) and policy (eg,
potential for free provision by the South African
Government). Then, between 5 and 10 ‘pre-pilot’ inter-
views will be carried out in each population to assess par-
ticipants’ understanding of background questions and
DCE choice tasks, explore the most meaningful
representations of attributes and levels, and identify any
issues with the tablet-based implementation of the DCE.
The pre-pilot stage will be critical in creating clear, rele-
vant and realistic choice sets which are presented to par-
ticipants in an understandable manner. The DCE to be
piloted is unlabelled, meaning all products will not be
presented at once, but each will appear as an available
alternative according to the experimental design. The
six attributes of the DCE and their levels are shown in
table 1.
We will include ﬁve new prevention products, chosen
to reﬂect the range of potential ARV delivery mechan-
isms. Some (eg, oral PrEP) are fully developed and are
in the later stages of global licensing, while others (eg,
injectables) are a few years from efﬁcacy trials and
potential roll-out. Women will be presented with the full
range of products, while men will only be presented
Figure 2 Study design. DCE, discrete choice experiment.
Table 1 Attributes and levels
Attribute Levels
Product Oral pre-exposure prophylaxis, microbicide gel, microbicide gel with SILCS diaphragm,
vaginal ring, injectable pre-exposure prophylaxis
HIV protection 55%, 75%, 95%
Pregnancy prevention Prevents pregnancy, does not prevent pregnancy
Frequency of use* Every time you have sex, once per day, once per week, once per month, once per
3 months, once per 6 months, once per year
Protection against other STIs Protects against other STIs, does not protect against other STIs
Side effects (probability of
occurrence fixed)
Stomach cramps/pain, nausea/feeling sick, dizziness, none
*As no product can be used at all frequencies, the design will contain constraint terms where only relevant frequencies will be presented
alongside products. Frequencies were chosen to be informative for product development: oral PrEP—daily, weekly, monthly; microbicide
gel—coitally; SILCS diaphragm and microbicide gel—coitally, daily; vaginal ring—weekly, monthly, three-monthly, six-monthly;
injection—three-monthly, six-monthly, annually.
SILCS; STI, sexually transmitted infections.
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with male-initiated options (ie, oral PrEP and inject-
ables). We include two products based on microbicide
gels, despite recent unsuccessful effectiveness trials.6 9
Trial results suggest that gels were efﬁcacious when used
adherently, however, many participants were not able to
use the products consistently enough as part of everyday
life. Including these products in the DCE will allow us to
explore how preferences for products vary by character-
istics, such as frequency of use and potential side effects,
and provide an opportunity to compare DCE predictions
to reality. We note that common side effects were
chosen through reports from PrEP trials and ART regi-
mens using ARV drugs.34 35
FGDs will be carried out with FSWs, as the risk factors
and sexual relationships of this group are likely to be
substantively different from other population, while it
was noted that there was a gap in the literature and in
local knowledge on FSW preferences. It is a limitation of
this study that we are unable to carry out FGDs with
men or adolescent women; however, we will use the
expertise and experience of local collaborators along-
side identifying substantive literature to assess relevant
attributes for these groups. In the FSW FGD, themes
related to HIV prevention choices and negotiation of
protection with clients and partners will be explored in
four FGDs with between 8 and 12 participants in each.
The qualitative data from the focus groups will then be
analysed using thematic analysis to inform the ﬁnal
version of the DCE survey tools.36 These discussions will
provide novel insights into decision-making by FSWs
around HIV prevention which have never been explored
in a DCE context before.
The DCE will be piloted through an initial fractional
factorial design which will be generated by specialist
NGENE software37 and tested face to face with a sub-
sample of 20 respondents, ﬁve from each population
group (men, women, adolescent girls and FSWs). These
pilots will aim to assess how well respondents understand
questions and responses, whether tablet-based enumer-
ation is feasible and reliable, and explore different pre-
sentations of DCE tasks and attributes. Furthermore, the
responses from these DCE tasks will be analysed using a
multinomial logit model (MNL) to obtain point esti-
mates of utility function parameters. These estimates will
be used in generating a statistically efﬁcient design for
the ﬁnal DCE.
The attributes and levels shown above yield 1260 pos-
sible product proﬁles, far too great a number to present
to all participants. Recent advances in DCE design have
led to the development of ‘efﬁcient’ designs which,
when informed by prior information from a pilot study
and/or the literature, offer more reliable parameter esti-
mates when compared with traditional orthogonal
designs. To ensure realistic choice data and avoid over-
estimating demand for new products,32 participants can
opt out of choosing a new product with a fourth alterna-
tive presented of ‘do what I did last time’ (ie, use a
condom or nothing). Since an unlabelled design is used
to reduce the number of choices within a set from six to
four, it is likely (and certain in the male DCE) that some
products will be presented twice in the same choice set,
with different attribute levels. Interviewers will be fully
trained to explain this nuance to participants.
Finally, data will be captured in the ﬁnal questionnaire
on salient background characteristics of participants
including: age, gender, quality of life, reproductive
history, relationship history and HIV knowledge. This
data will allow the analysis of how preferences are
shaped by life circumstances, for example, if a respond-
ent is seeking to conceive with a partner. Through
framing choice tasks around the last sex act, we will be
able to explore how preferences may vary by partner
type, for example, between non-commercial and com-
mercial partners of FSWs, or between long-term and
short-term sexual relationships. Data will also be gath-
ered on the gender of respondents’ most recent sexual
partner. The piloting process will inform which
characteristics should be included in ﬁnal data analysis
as explanatory variables for preferences in HIV preven-
tion products. Finally, we note that while trials of some
products (oral PrEP and a vaginal ring) will be ongoing
in some populations in South Africa during this study,38
the geographically concentrated and research-naive
populations chosen for this work are very unlikely to
have experience of using these (eg, through participa-
tion in trials). We will record if participants have prior
experience of using any of these products.
Stage 2: administration of DCE
Participants and recruitment
The survey and DCE will be administered using Open
Data Kit (https://opendatakit.org/) software on
tablet computers. The acceptability and feasibility of
tablet-based data collection will be assessed during the
formative stage, although it is expected that it will min-
imise missing data, and reduce laborious data entry and
cleaning.39 40 Participants will be given a ZAR 50 (GBP
£2.50) voucher as compensation for their time.
Participants will be asked to self-report their HIV status,
and we aim to maximise accuracy in reporting through
careful conﬁdentiality and sensitivity training of the
interviewer team, which has considerable experience in
collection of HIV and sexual health data.
To ensure that choices are relevant and meaningful to
participants, three steps will be taken to maximise the
realism of choice scenarios. First, all interviewers will be
equipped with a full set of example products: a real
SILCS diaphragm, alongside placebo PrEP tablets (simi-
larly coloured, shaped and sized), vaginal rings, microbi-
cide gels and injections (an empty syringe). Participants
will be encouraged to touch and explore the products as
much as they wish before beginning choice tasks.
Second, interviewers will be thoroughly trained and
tested on how to describe products to participants. In
addition, concise and clear information sheets will be
used when explaining the tasks, products and attributes.
Quaife M, et al. BMJ Open 2016;6:e010682. doi:10.1136/bmjopen-2015-010682 5
Open Access
group.bmj.com on July 9, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Third, the statistical design of the DCE will be such that
only relevant products are presented to different groups,
and relevant attributes for different products. For
example, only injectable and PrEP options will be pre-
sented to men, while the frequency of injections will be
restricted to between once per month and once per
year.
If participants choose an ARV-based, non-condom
product, they will subsequently be asked whether or not,
if the product was available, they would have used it the
last time they had sex. If they indicate that they would,
they will be asked whether they would have used it
alongside, or instead of, a condom. This will enable us
to ascertain whether new products will be used in com-
bination with, or in substitute of, condoms. Since there
is likely to be no additional beneﬁt from dual use of
ARV-based products, nor would medical advice suggest
this would be something users should do, the DCE
framework does not allow for the combination use of
ARV-based products, except the SILCS diaphragm which
is used in concert with gel.
Primary data will be collected in Ekhurhuleni
Metropolitan Municipality, Gauteng Province. The
Municipality was selected as the study site because it con-
tains a broad range of residential contexts, representing
a range of demographic, socioeconomic and cultural
characteristics. We employ a proportional cluster sam-
pling strategy, stratiﬁed by population. For the 200 men
and 200 women, the nature of the household sampling
method means that we may be able to interview both
cohabiting partners in a relationship; assuming a sufﬁ-
cient number of individuals in cohabiting relationships
are available and consent to participate, analysis of pre-
ferences within relationships would be a particularly
novel element of this research.
Different enumeration teams will interview respon-
dents from each group. For the general population, a
specialist local data collection ﬁrm with over 20 years of
experience, Progressus Research and Development
(http://www.progressus.co.za/), will manage the survey
process, generate the sampling design, and carry out the
DCE. On ﬁnding an adult present in a household, the
interviewer will identify him/herself, explain the study,
and request permission to note down all women, men
and adolescent girls living in the house ordered by age.
We expect the whole survey, including DCE, will take
around 30–45 min to complete.
Two hundred FSWs will be recruited through RDS. We
will employ peer educators who will ﬁrst locate sex work
‘hotspots’ in the Vosloorus area, before selecting 7–10
seeds among FSWs operating in different areas such that
different social networks are reached (eg, FSWs working
in brothels, on the street or in bars or taverns). These
women will be invited to participate in the study and
given a ZAR 50 (GBP £2.50) voucher as compensation
for their time, before receiving three coupons contain-
ing the study information to distribute to colleagues.
When one of these colleagues attend the study site, both
they and their recruiter receive a small incentive in the
form of a ZAR 20 (GBP £1) voucher. The amount of
compensation was based on similar studies among FSWs
in South Africa, and is designed to be high enough to
compensate for potential loss of one client during study
participation, but not so high as to encourage signiﬁcant
fraudulent enrolment.
Sample size
The DCE literature has not yet reached consensus on
the best way to successfully estimate the sample size
required in a DCE study to return meaningful, statistic-
ally robust parameter estimates. Applying the popular
rule of thumb of Johnson and Orme,41–43 we estimate
that a sample size of 90 should be sufﬁcient to estimate
parameters of the DCE structure shown in ﬁgure 1.
Similarly, the literature suggests that between 20 and 30
observations per choice set can provide precise param-
eter estimates.18 44 This indicates that our sample size of
800 will be sufﬁcient to estimate parameters over the
entire population, as well as to explore any variations in
preferences which might exist between groups.
Stage 3: data analysis
Results from this study will aid future development and
rollout of HIV prevention products by identifying key
product attributes likely to inﬂuence an individual’s
decision to use such products. Although there are a
number of ways to analyse DCE data, the literature gen-
erally advises to start with a simple MNL model, and
progressively explore other model speciﬁcations.32 A
notable restriction of the MNL model is that it assumes
the ‘irrelevance of independent alternatives’ (IIA), spe-
ciﬁcally that the odds of choosing one class over another
does not depend on the wider set of alternatives. This is
often not realistic, and we will employ discrete choice
models such as the mixed MNL (MMNL) and general-
ised MNL (GMNL) models. These relax some assump-
tions of the MNL model (including the IIA restriction)
as model coefﬁcients are allowed to vary over individuals
through the inclusion of stochastic components. Choice
data from this study will be analysed through MNL,
MMNL, nested logit and generalised MMNL models to
fully explore heterogeneity in the data.32
Interactions between DCE attributes and respondent
characteristics (such as the interaction between per-
ceived HIV risk and preferences for product efﬁcacy)
will be explored by their inclusion as explanatory vari-
ables when estimating utility functions. Model results
will be presented as parameter estimates with SEs. The
marginal rate of substitution between attributes will also
be calculated.
Finally, the RDS sample among FSWs will be analysed
with consideration of the non-random, chain-referral
nature of the data through mathematical weighting to
compensate for non-random participant recruitment.
RDS data require a number of assumptions to hold for
statistical inferences to be valid; however, when
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attempting to reach hidden populations such as FSWs,
RDS is an increasingly popular and reasonably robust
method.31 45
ETHICS AND DISSEMINATION
Ethical considerations
This study has been reviewed and approved by the
University of the Witwatersrand Human Research Ethics
Committee and the Research Ethics Committee at the
London School of Hygiene and Tropical Medicine. All
participation in the DCE, alongside supporting qualita-
tive studies will be voluntary and subject to completion
of written informed consent. When interviewing adults
in households where adolescent girls aged 16–17 years
are present, interviewers will ask for assent from the
young woman, aim to obtain guardian consent, and
interview the adolescent. The informed consent pro-
cesses will be administered in private (including from a
parent or guardian of an adolescent subject). A compre-
hensive distress protocol will ensure that participants
who reveal distressing or harmful events during the
survey will be referred to named persons at local clinics
and NGOs.
All information provided by respondents will be kept
secure and conﬁdential. Paper-based informed consent
forms and household survey frames will be kept separ-
ately from questionnaire data to protect the identity of
the participants. Participants do not need to use their
real names in any of the interview formats, while the
background survey will not collect any identiﬁable infor-
mation from respondents outside of salient socio-
economic and sexual history characteristics. It will be
made clear to all participants that they have the right to
withdraw from the research at any point in time.
Participants will be informed that there is no immediate
beneﬁt to them for taking part in the study, but that the
information they give can help develop future products
and services. Participants will receive a ZAR 50 (£2.50)
voucher as a token of appreciation for their time.
DISSEMINATION
Results will be published through peer-reviewed journals
and via national and international conference presenta-
tions. Meetings will be held with opinion leaders in
South Africa and organisations working in the area of
HIV prevention. Results will be disseminated to partici-
pants in Ekurhuleni through a public meeting or news-
letter; extra care will be taken here to ensure participant
anonymity.
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